Country: Canada
Language: English
Source: Health Canada
DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE)
JAMP PHARMA CORPORATION
S01EC03
DORZOLAMIDE
20MG
SOLUTION
DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20MG
OPHTHALMIC
15G/50G
Prescription
CARBONIC ANHYDRASE INHIBITORS
Active ingredient group (AIG) number: 0128558001; AHFS:
APPROVED
2021-11-15
_Dorzolamide_ _ _ _(dorzolamide hydrochloride) _Page 1 of 28 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR DORZOLAMIDE Dorzolamide Hydrochloride Ophthalmic Solution, USP 20 mg/mL Dorzolamide (as Dorzolamide Hydrochloride) Elevated Intraocular Pressure Therapy (Topical Carbonic Anhydrase Inhibitor) JAMP Pharma Corporation 1310 rue Nobel Boucherville, Quebec J4B 5H3, Canada Date of Initial Authorization: November 15, 2021 Date of Revision: October 12, 2023 Submission Control Number: 275514 _Dorzolamide_ _ _ _(dorzolamide hydrochloride) _Page 2 of 28 RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ................................................................................................. 2 TABLE OF CONTENTS .................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................... 4 1 INDICATIONS .................................................................................................................... 4 1.1 Pediatrics ..................................................................................................................... 4 1.2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ....................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ....................................................................................... 4 4.1 Dosing Considerations .................................................................................................. 4 4.2 Recommended Dose and Dosage Adjustment ............................................................... 4 4.4 Administration ........................................ Read the complete document